Bind Therapeutics (BIND) Stock: Heres What You Need To Know

Bind Therapeutics (NASDAQ:BIND) On July 1, 2016 Bind Therapeutics announced that it had agreed to a stalking horse bid from Pfizer. The company said that it had filed a motion in court for a purchase agreement whereby Pfizer would acquire Bind’s assets. Investors greatly cheered this news and the stock nearly doubled to 0.78 cents … Read more

Biotech Stock News (PFE) (ANAC) (ADRO) (ADXS)

Pfizer (NYSE:PFE) On Monday May 16, 2016 Pfizer had announced that it would acquire Anacor Pharmaceuticals (NASDAQ:ANAC) for $5.2 billion. Translating the $5.2 billion amount to stock, would make it a buyout at $99.25 per share. When this deal was first announced, Anacor was trading in the mid 60’s level. Why exactly did Pfizer feel … Read more

Biotech Stock News (AGN) (PFE) (ICPT)

Allergan (NYSE:ACT) & Pfizer (NYSE:PFE) On April 5, 2016 shares of Allergan had tumbled by 14.77% as investors had become skeptical that the deal with Pfizer would actually go through. The reason for  investors becoming skeptical was because the government had implemented new tax inversion rules. Back in November Pfizer brokered a deal to buy … Read more

Biotech Stock News (ONCE) (AAVL) (CLDN) (ADXS) (OPK) (PFE)

Spark Therapeutics (NASDAQ:ONCE) On October 5, 2015 shares of Spark Therapeutics ended the day up at least 25% after the company announced that it had achieved positive phase 3 results in patients with a rare form of blindness. This rare form of blindness stems from a mutation in the RPE65 gene of the eye which … Read more

Why Pfizer (PFE) Is A Great Investment Choice These Days

Pfizer (NYSE: PFE) Pfizer has been a very interesting stock to follow this year. While the stock didn’t see much growth throughout the year 2014, that hasn’t necessarily been the case for 2014 as investors have been excited about the big moves the company is making toward growth. For example, Monday and Tuesday, the company … Read more

Biotech Stock News (AAVL) (AERI) (AGN) (KYTH) (RHHBY) (REGN) (PFE) (NVS)

Avalanche Biotech (NASDAQ:AAVL) Shares of Avalanche Biotech fell as much as 40% in after-hours trading on June 15, 2015 after the company announced results from its phase 2 wet-age related macular degeneration — wet-AMD — trial. The drop is huge but many investors should be assured that the drop was justified because the results were … Read more

Biotech Stock News (ARWR)(AMGN)(ATHX)(PFE)

Arrowhead Research Corp (NASDAQ:ARWR) On April 13, 2015 Arrowhead announced that it was given the go-ahead by the FDA to begin treating patients in the phase 2b Hepatitis B study.  The drug compound being used in the study is known as ARC-520 which is an RNAi drug. RNAi stands for RNA interference and these types … Read more

April Earnings To Watch | ABBV | GILD | PFE | MRK

April is more than half way over. However, the most exciting part of the month for many is soon to come! As we move into earnings season, big names in health care are getting set to release their reports. Below are a few earnings reports that I’ll be watching closely and what I expect to … Read more

Biotech News- 2/9/15 to 2/13/15

Achillion Pharmaceuticals (ACHN) Shares of Achillion gained 7% on 2/9/15 last week when it had announced that it had achieved a 100% SVR12 in a phase 2 trial treating patients with the genotype 1 version of the Hepatitis C virus — HCV. The trial tested for the primary objective of patients being able to achieve a … Read more